Please substitute the following claims 1, 5-7, 20, 44, 66, 74 and 76-78 for the pending claims 1, 5-7, 20, 44, 66, 74 and 76-78:

1. (Once amended) A pharmaceutical composition, comprising:

(a) a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2 in a concentration range of about 0.02 to about 40 mg/ml (w/v);

(b) a buffer having a buffering capacity of about pH 5.0 to about pH 8.0 at a concentration range of about 5 mM to about 50 mM;

(c) a pharmaceutically acceptable diluent to bring the composition to a designated volume; and

(d) a preservative selected from the group consisting of m-cresol, chlorobutanol, and a mixture of methyl paraben and propyl paraben;

or a reaction product thereof.

~~5.~~ (Once amended) The pharmaceutical composition of claim 1, wherein said polypeptide is present in a concentration range of about 0.05 to about 30 mg/ml (w/v).

~~6.~~ (Once amended) The pharmaceutical composition of claim ~~5~~, wherein said polypeptide is present in a concentration range of about 0.1 to about 20 mg/ml (w/v).

~~7.~~ (Once amended) The pharmaceutical composition of claim ~~6~~, wherein said polypeptide is present in a concentration range of about 0.2 to 4 mg/ml (w/v).

20. (Once amended) The pharmaceutical composition of claim 1, wherein said polypeptide is selected from the group consisting of: (i) Ser (69) - Ser (208) of SEQ ID NO:2; (ii) Ser (69) - Ser (208) of SEQ ID NO:2 with a methionine at the N-terminus; and (iii) a mixture of (i) and (ii).

a10

~~44~~ 48. (Once amended) The pharmaceutical composition of claim ~~40~~ 39, wherein said thickening agent is a water soluble etherified cellulose or a carbomer.

a11

~~56~~ 63. (Once amended) The pharmaceutical composition of claim 1, wherein said polypeptide is present in a concentration range of about 0.01 mg/ml to about 10 mg/ml (w/v).

a12

~~74~~ 67. (Once amended) A pharmaceutical composition comprising:

(a) about 1.0 mg/ml of a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2;

(b) 20 mM citrate, pH 5-5.5; and

(c) 0.01% polysorbate 80.

a13

Sub B4 76. (Once amended) A pharmaceutical composition comprising:

(a) about 3.3 mg/ml of a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2;

(b) 10 mM sodium citrate

(c) 20 mM sodium chloride;

a14

(d) 1 mM EDTA

(e) 2% w/v glycine;

(f) 0.5% w/v sucrose;

(g) water; and

(h) pH about 6.2;

or a reaction product thereof.

77. (Once amended) The pharmaceutical composition of claim 76, wherein over 90% of the water is removed by lyophilization.

78. (Once amended) A pharmaceutical composition comprising:

(a) about 1.0 mg/ml of a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2;

(b) 10 mM sodium citrate;

(b) 0.46% hydroxyethylcellulose;

(c) 7% sucrose;

(d) 20 mM sodium citrate;

(e) 20 mM sodium chloride;

(f) 1 mM EDTA; and

(g) pH about 6.2;

or reaction products thereof.

Please add the following claims:

69 ~~79~~. (New) The pharmaceutical composition of claim 67 ~~74~~, wherein said polypeptide is selected from the group consisting of: (i) Ser (69) - Ser (208) of SEQ ID NO:2; (ii) Ser (69) - Ser (208) of SEQ ID NO:2 with a methionine at the N-terminus; and (iii) a mixture of (i) and (ii).

a15

71 ~~80~~. (New) The pharmaceutical composition of claim 70 ~~76~~, wherein said polypeptide is selected from the group consisting of: (i) Ser (69) - Ser (208) of SEQ ID NO:2; (ii) Ser (69) - Ser (208) of SEQ ID NO:2 with a methionine at the N-terminus; and (iii) a mixture of (i) and (ii).

74 ~~81~~. (New) The pharmaceutical composition of claim 73 ~~78~~, wherein said polypeptide is selected from the group consisting of: (i) Ser (69) - Ser (208) of SEQ ID NO:2; (ii) Ser (69) - Ser (208) of SEQ ID NO:2 with a methionine at the N-terminus; and (iii) a mixture of (i) and (ii).